Therapeutic Response

PDGFRA p.D842V status confers therapeutic sensitivity to Avapritinib in patients with Gastrointestinal Stromal Tumor.

Statements

Source and description
Ayvakit (avapritinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to avapritinib for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.